BioXcel Therapeutics Inc (BTAI) support and resistance · rev $388.0K
BioXcel Therapeutics Inc (BTAI) is a drug manufacturers - specialty & generic company listed on US.
This page maps BioXcel Therapeutics Inc (BTAI) support and resistance from cached range and valuation — not a live tape and not a trade alert.
Latest reported BTAI revenue for 2026-06-30 was $388.0K. Net income was -$27.4M. Revenue was up 88.3% from 2026-03-31 to 2026-06-30. BTAI currently screens at market cap $36.1M.
BTAI currently screens at market cap $36.1M. Round numbers near that cap and multiple often act as psychological resistance; prior-period revenue is the fundamental floor traders argue about.
A new BTAI 8-K or 10-Q can move the levels that matter more than a drawing on a chart.
Not investment advice. Use the BTAI quote page for the session range and the stock page for the full model.
Not investment advice.